KEMYTH BIOTECH


KeMyth Biotech, established in July 2015, focuses on transforming research achievements into industry innovation. The company has expanded its focus from infectious diseases to broader health challenges, developing core projects such as antibiotic testing and screening platforms, rapid diagnostic reagents, new drug development, and beauty and health products. With a professional team and industry partnerships, KeMyth Biotech aims to enhance medical quality, improve human health and quality of life, and lead the development of the biotech industry through continuous innovation and global market expansion.

Industries

beauty
biotechnology
health-care
health-diagnostics

Nr. of Employees

small (1-50)

KEMYTH BIOTECH


Patents

Antibiotic testing and screening system

US-10760110-B2

View Details

Treatment of diabetes, toll-like receptor 4 modulators and methods for using the same

US-10287328-B2

View Details

Products

Antibiotic testing and screening platform

Platform to evaluate and screen antibacterial compounds for antimicrobial activity and candidate selection.

Klebsiella pneumoniae K1/K2 serotyping antigen diagnostic reagent

Antigen-based diagnostic reagent for serotyping Klebsiella pneumoniae capsular types K1 and K2.

Cosmetics and health product line (natural-extract formulations)

Series of natural-extract cosmetic and health products developed using advanced extraction techniques and formulation methods.


Services

Contract preclinical PK and biodistribution studies to determine ADME and tissue distribution of compounds.

Expertise Areas

  • Antibiotic screening and susceptibility testing
  • Diagnostic reagent development and serotyping
  • Pharmacokinetics and biodistribution studies
  • Natural product extraction and formulation
  • Show More (3)

Key Technologies

  • Antibiotic screening platforms
  • Antigen-based diagnostic assays
  • Bacterial capsular serotyping assays
  • Pharmacokinetic and biodistribution assays
  • Show More (2)

News & Updates

Approval for medical equipment.

Obtained Taiwanese patent for the antibiotic testing and screening platform (Invention No. I778025).

Obtained US patent for the antibiotic testing and screening platform (Patent No. KMB0002US).

Received the 13th Taiwan National Innovation Award for rapid identification technology of Klebsiella pneumoniae capsule serotype.

Received the 13th Taiwan National Innovation Award for rapid identification technology of Klebsiella pneumoniae capsule serotype.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.